Page last updated: 2024-12-05

dpi 201-106

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DPI 201-106: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5190
CHEMBL ID314639
CHEBI ID110175
SCHEMBL ID2197158
MeSH IDM0134116

Synonyms (59)

Synonym
CBIOL_001886 ,
4-{3-[4-(diphenylmethyl)piperazin-1-yl]-2-hydroxypropoxy}-1h-indole-2-carbonitrile
sdz-201106
CHEMBL314639 ,
BRD-A64553394-001-02-8
dpi-201106
1h-indole-2-carbonitrile, 4-(3-(4-(diphenylmethyl)-1-piperazinyl)-2-hydroxypropoxy-, (+-)-
(+-)-4-(3-(4-(diphenylmethyl)-1-piperazinyl)-2-hydroxypropoxy)-1h-indole-2-carbonitrile
BIO2_000195
BIO1_001150
BIO1_000172
BIO1_000661
BIO2_000675
IDI1_033945
BSPBIO_001475
NCGC00163143-01
NCGC00163143-02
dpi 201-106
KBIOGR_000195
KBIO3_000390
KBIO2_005331
KBIO2_002763
KBIO3_000389
KBIOSS_000195
KBIO2_000195
CHEBI:110175
HMS1989J17
AKOS000278277
HMS1361J17
HMS1791J17
97730-95-5
4-[3-(4-benzhydryl-piperazin-1-yl)-2-hydroxy-propoxy]-1h-indole-2-carbonitrile
4-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropoxy)-1h-indole-2-carbonitrile ,
bdbm50001689
4-[3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropoxy]-1h-indole-2-carbonitrile
NCGC00163143-03
dpi-201-106
unii-ui0ep1d878
ui0ep1d878 ,
SCHEMBL2197158
HMS3402J17
sdz-201106 (+/-), (dpi-201106)
Q27189556
dpi201-106
AKOS030548174
1h-indole-2-carbonitrile, 4-(3-(4-(diphenylmethyl)-1-piperazinyl)-2-hydroxypropoxy)-
4-(3-(4-(diphenylmethyl)-1-piperazinyl)-2-hydroxypropoxy)-1h-indole-2-carbonitrile
dpi-201-106, (+/-)-
DTXSID10913677
racemic dpi 201-106
dpi 201-106;sdz 201106
4-[3-[4-(diphenylmethyl)-1-piperazinyl]-2-hydroxypropoxy]-1h-indole-2-carbonitrile
97730-95-5 (racemic)
4-[3-(4-diphenylmethyl-1-piperazinyl)-2-hydroxypropoxy]-1h-indole-2-carbonitrile
MS-28604
CS-0016178
HY-19666
sdz 201106
sdz-201106(+/-),(dpi-201106)

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" Nicardipine and two new cardiotonic agents, APP 201-533 and DPI 201-106, interact with the N-terminal domain of troponin C, and either do not affect or, in the case of DPI 201-106, slightly increase the affinity of the Ca(2+)-specific site of troponin C for Ca2+ ion."( Drug interaction with cardiac and skeletal muscle troponin C.
Geguchadze, RN; Gusev, NB; Krylatov, AV, 1990
)
0.52

Dosage Studied

ExcerptRelevanceReference
" A second set of measurements was performed with administration of the threefold dosage of either substance."( Characterization of the inotropic and arrhythmogenic action of the sodium channel activator BDF 9148: a comparison to its S-enantiomer BDF 9196, to its congener DPI 201-106, to norepinephrine, and to ouabain.
Baumgart, D; Ehring, T; Heusch, G; Krajcar, M; Skyschally, A,
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency39.81070.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency6.71030.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency25.28550.180013.557439.8107AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
survival motor neuron protein isoform dHomo sapiens (human)Potency28.18380.125912.234435.4813AID1458
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency11.22021.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorHomo sapiens (human)Ki0.05730.00000.66359.5499AID389416
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (32)

Processvia Protein(s)Taxonomy
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (51)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID62807Total peripheral resistance was tested in anesthetized dogs for a dose of 1.0 mg/kg1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID217786Inactivation processes of human heart Na channel expressed in Xenopus oocytes as increase in current at 10 uM1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and structure-activity relationships of 6-heterocyclic-substituted purines as inactivation modifiers of cardiac sodium channels.
AID59179The compound was tested for its cardiovascular activity expressed as heart rate in beat/min in anesthetized dogs for a dose of 1.0 mg/kg1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID75922Coronary flow activity in Langendorff perfused guinea pig heart1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID324583Increase in long-lived protein degradation in human H4 cells after 2 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID62805Total peripheral resistance was tested in anesthetized dogs for a dose of 0.1 mg/kg1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID217781Effective concentration against Xenopus oocytes expressing guinea pig heart Na channel1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and structure-activity relationships of 6-heterocyclic-substituted purines as inactivation modifiers of cardiac sodium channels.
AID176036The compound was tested for its cardiovascular activity in rat heart model. producing a 50% increase (EC50) in LV dP/dtmax (measure of contractility).1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID59814Effective dose required to produce 50% increase of cardiac force in dog after administering ca. 1.875 mg/Kg drug intravenously1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and SAR of 6-substituted purine derivatives as novel selective positive inotropes.
AID324371Induction of light chain 3-GFP level in human H4 cells at 5.4 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID217787Effective concentration against Xenopus oocytes expressing human heart Na channel1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and structure-activity relationships of 6-heterocyclic-substituted purines as inactivation modifiers of cardiac sodium channels.
AID324585Increase in long-lived protein degradation in human H4 cells after 24 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID324527Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 5.4 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID324584Increase in long-lived protein degradation in human H4 cells after 4 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID324475Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 5.4 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID59160Heart rate in dog after administering ca. 1.875 mg/Kg drug intravenously1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and SAR of 6-substituted purine derivatives as novel selective positive inotropes.
AID389416Displacement of [3H]DHA from human beta2 adrenoceptor by liquid scintillation counter2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds.
AID60316The compound was tested for its cardiovascular activity in anesthetized dogs producing a 25% increase (EC25) in LV dP/dtmax (measure of contractility) for a dose of 1.0 mg/kg1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID72701In vitro changes in contractile force (CF) quantitated by determining the maximal increase in isometric tension by using ferret papillary muscle1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and SAR of 6-substituted purine derivatives as novel selective positive inotropes.
AID59028Mean arterial blood pressure in dog after administering ca. 1.875 mg/Kg drug intravenously.1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and SAR of 6-substituted purine derivatives as novel selective positive inotropes.
AID167259Antiarrhythmic activity was determined by measuring the concentration that produced a 20 ms increase in ERP1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and structure-activity relationships of 6-heterocyclic-substituted purines as inactivation modifiers of cardiac sodium channels.
AID59177The compound was tested for its cardiovascular activity expressed as heart rate in beat/min in anesthetized dogs for a dose of 0.1 mg/kg1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID60314The compound was tested for its cardiovascular activity in anesthetized dogs producing a 25% increase (EC25) in LV dP/dtmax (measure of contractility) for a dose of 0.1 mg/kg1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID166192Concentration which increased contractility by 20% in rabbit; no effect at 1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and structure-activity relationships of 6-heterocyclic-substituted purines as inactivation modifiers of cardiac sodium channels.
AID324577Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 4 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID175314The compound was tested for its cardiovascular activity in rat heart model. producing a 25% increase (EC25) in CF(coronary flow).1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID217782Inactivation process of guinea pig cardiac Na channels expressed in xenopus oocytes was determined by measuring increase in current integral in presence of compound versus control at 10 uM1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Synthesis and structure-activity relationships of 6-heterocyclic-substituted purines as inactivation modifiers of cardiac sodium channels.
AID59916Mean blood pressure was tested in anesthetized dogs. for a dose of 1.0 mg/kg1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID175316The compound was tested for its cardiovascular activity in rat heart model. producing a 25% increase (EC25) in LV dP/dtmax (measure of contractility).1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID324423Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 5.4 uM after 24 hrs by high throughput fluorescence microscopy relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID181664Calcium channel binding activity against dihydropyridine receptor in rat brain cortical membranes1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID60313The compound was tested for its cardiovascular activity in anesthetized dogs producing a 25% increase (EC25) in LV dP/dtmax (measure of contractility) for a dose of 0.01 mg/kg1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID324582Increase in long-lived protein degradation in human H4 cells after 1 hr relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID324578Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 8 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID167206Calcium channel blocking activity in rabbit aortic rings1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID176034The compound was tested for its cardiovascular activity in rat heart model. producing a 25% increase (EC50) in CF(coronary flow); NA = not achieved1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID59176The compound was tested for its cardiovascular activity expressed as heart rate in beat/min in anesthetized dogs for a dose of 0.01 mg/kg1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID59913Mean blood pressure was tested in anesthetized dogs. for a dose of 0.01 mg/kg1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID56098Cardiac force in dog after administering ca. 1.875 mg/Kg drug intravenously.1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and SAR of 6-substituted purine derivatives as novel selective positive inotropes.
AID61747dP/dt max was determined in dog1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and SAR of 6-substituted purine derivatives as novel selective positive inotropes.
AID62804Total peripheral resistance was tested in anesthetized dogs for a dose of 0.01 mg/kg1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID59914Mean blood pressure was tested in anesthetized dogs. for a dose of 0.1 mg/kg1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds.
AID324576Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 2 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48
Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID72698Relative change in CF was determined by calculating the effective concentration that produced a 50% of maximum increase in tension1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and SAR of 6-substituted purine derivatives as novel selective positive inotropes.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (99)

TimeframeStudies, This Drug (%)All Drugs %
pre-199044 (44.44)18.7374
1990's41 (41.41)18.2507
2000's9 (9.09)29.6817
2010's3 (3.03)24.3611
2020's2 (2.02)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 14.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index14.78 (24.57)
Research Supply Index4.69 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (14.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (3.85%)5.53%
Reviews1 (0.96%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other99 (95.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]